Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 - CTA Approval BT-001 - EN
20201221 - CTA Approval BT-001 - EN
20201216 PR Investors Meeting agenda Jan 2021
20201203 - TG4001 mini oral prez ESMO IO EN
20201203 - Nomination Transgene - EN
Franck Gallardo, et al. Biomedicines, November 26 2020 - Read [...]
20201109 Transgene BioInvent_SITC BT001_EN
20201109 - TG4001+avelumab presentation poster SITC - EN
Poster BT-001 M. Semmrich et al. SITC 2020 Download the [...]
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 [...]